Starling Oncology

Starling Oncology, established in 2007, operates as a specialized oncology healthcare services provider. The firm focuses on delivering value-based cancer care through an integrated network of clinics and affiliated medical providers. By prioritizing evidence-based oncology treatments, the organization facilitates clinical trials, transfusions, and comprehensive patient care coordination. This model aims to improve health outcomes by streamlining the delivery of complex cancer therapies within community-based settings.

The company maintains a workforce of 500-1,000 employees dedicated to high-quality patient outcomes. Operating from a single primary location, Starling Oncology leverages its centralized infrastructure to manage patient care pathways effectively. The organization’s operational strategy emphasizes the integration of clinical services to ensure that patients receive consistent, evidence-based support throughout their treatment journey. This focused approach allows for specialized care delivery that addresses the unique needs of oncology patients.

Publicly traded under the ticker NASDAQ: STLN, Starling Oncology continues to expand its influence within the healthcare sector. The company’s commitment to value-based care models positions it as a significant player in the oncology services market. Meet Starling Oncology's team to learn more about the leadership driving these clinical initiatives. With a clear focus on evidence-based medicine and patient-centric services, the organization remains dedicated to advancing cancer care standards and improving the quality of life for patients across the region.